News

Martin Lehr 12/8/18 Martin Lehr 12/8/18

Context Therapeutics Announces New Preclinical Data on Apristor at San Antonio Breast Cancer Symposium

Deepak Lala, Tasir Haque, Hannah Feinman, Jianhong Wu, Yuren Wang, Amy Dwyer, Thu Truong and Carol Lange

Martin Lehr 12/7/18 Martin Lehr 12/7/18

The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models

Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange

San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018

Martin Lehr 11/13/18 Martin Lehr 11/13/18

Context Announces Presentation of New Preclinical Data on Apristor in Combination with a Cdk4/6 Inhibitor at San Antonio Breast Cancer Symposium

Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on Apristor®, its first-in-class full progesterone receptor antagonist, will be featured at the San Antonio Breast Cancer Symposium® taking place on December 4-8, 2018 in San Antonio, TX.